AzTrials
AzTrials

HIV InfectionsIMPERATIVENCT06370923

Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention

A study testing Peer Distribution and Community Health Worker Distribution in people with HIV Infections, run by University of Stellenbosch at 1 site in Zimbabwe.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Novel strategies are needed to engage men in Sub Saharan Africa (SSA) with HIV testing, treatment and prevention services to drive the epidemic towards elimination. Suboptimal engagement with HIV prevention by men increases their risk of HIV acquisition, and is an important driver of new HIV infections in women. Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
Conditions the study is for
HIV Infections
What is being tested?
Peer Distribution and Community Health Worker Distribution
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3,591 participants
Where
1 siteZimbabwe
Study dates
21 Oct 2024to 31 May 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Resident in study site

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Constance Nyamukapa, PhD contact

+263 71 480 4050

nyamukapaconnie@gmail.com

Zimbabwe1 site, 1 recruiting
  • BRTI - Manicaland Centre for Public Health Research

    Mutare, Manicaland Province

    Constance Nyamukapa, PhD, nyamukapaconnie@gmail.com

    Recruiting

Other trials in Zimbabwe

About this study

Official title: Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention: A Large-scale Cluster Randomized Trial to Increase HIV Self-testing and PrEP Uptake Among Men in Eastern Zimbabwe

Novel strategies are needed to engage men in Sub Saharan Africa (SSA) with HIV testing, treatment and prevention services to drive the epidemic towards elimination. Suboptimal engagement with HIV prevention by men increases their risk of HIV acquisition, and is an important driver of new HIV infections in women. HIV self-testing (HIVST) addresses several key facility-based access barriers and HIVST distribution through leveraging male peer networks for HIV prevention is feasible, acceptable and effective in SSA.

The objective of this project is to use an implementation science approach to establish the impact of HIVST distribution through male social networks, with phone-based support and improved risk perception, on PrEP (Pre-Exposure Prophylaxis) uptake among men in Eastern Zimbabwe. The project will leverage infrastructure and data associated with 20-year programme of HIV surveillance and behavioural research in a well-characterized population cohort hosted by the Manicaland Centre for Public Health Research, Zimbabwe.

The study will utilise a cluster randomised design of 44 clusters (22 Intervention:22 control) comprising on average 81 men in each cluster (total N = 3591) followed for 6 months (giving >80% power to detect a difference in PrEP initiation among men of 2% versus 8.5%). In intervention clusters the investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS (Short Message Service) -based risk assessment will expedite PrEP initiation at the clinic. The study team will conduct a performance (process) evaluation of the intervention. to assess implementation fidelity, causal mechanisms underlying trial effectiveness including how characteristics of peer networks affect outcomes. Results of the study will be used to quantify the population level impacts and cost-effectiveness of male peer to peer HIVST distribution strategies on the uptake of PrEP in HIV hyper-endemic settings using a fully calibrated individual-based mathematical model. The envisaged long-term impact of this research is the development of a generalizable, multicomponent male peer-based HIVST and PrEP uptake model for settings where HIV incidence is high.

Read the detailed description

The study will use a cluster-randomised trial design with clusters based on existing village boundaries, which have been utilised as part of an ongoing population-based HIV surveillance. In some cases, neighbouring villages will be aggregated to give approximately equal numbers of adult men in each cluster.

The study cohort from which participants will be recruited is located in Manicaland province, east Zimbabwe.

The intervention will proceed with the following steps:

  1. Potential primary distributors will be identified by the research team following engagement with local key informants, these individuals will be contacted and screened for study enrolment. The desired characteristics of these individuals would be that they are members of their community with strong local networks of peers. If they choose to participate an informed consent procedure will be completed by the fieldworkers. ii. If enrolled, the distributor will be given a pack containing four HIVST kits, one for their own use and three for distribution within the cluster. The study team will collect basic demographic data (name/age / cell number) for the distributor and the intended recipients. They will also record the unique ID of the pack of kits. Advice will be provided on the correct use and interpretation of the HIVST, the need for post-test confirmatory testing in a health facility and the availability of HIV prevention methods including PrEP. iii. The distributor will be asked to give the test kits to the intended recipients within a seven-day period. iv. After seven days the helpdesk will contact the distributor and the intended recipients to ascertain whether kits have been received and used, to collect behavioural HIV risk data for the recipients and encourage attendance at a healthcare facility for a confirmatory test. If they have not yet distributed the test kits, the helpline will follow-up at regular intervals to see if distribution has happened. HIVST recipients will be invited to complete the informed consent over the telephone and be enrolled in the study. Follow-up calls will be made to these individuals if necessary. Recipients will be encouraged to consider becoming distributors and advised on the location of community facilities (shops, pharmacies, hairdressers etc.) from where they can obtain the HIVST packs for distribution. This method of HIVST distribution through community-based hubs has been proven to be successful in studies in other Sub-Saharan African settings. [48] A small incentive of USD1:00 will be transferred electronically to the initial distributor for each kit successfully distributed. Successful distribution to peers is defined as the peer having received the HIVST and has been successfully contacted by the helpline to confirm receipt of the HIVST but does not have to use the HIVST or agree to enrol in the study as a distributor. Names and cell numbers will be collected for intended recipients by the study team and stored confidentially.
  2. If the recipient chooses to become a distributor, they will go to the community facility and the owner will check using a real-time database that they are eligible. If they pass this screening, they will be given a pack of three HIVST kits for within cluster distribution. If distributors successfully distribute all three HIVST kits within their clusters, they will have the option to collect a further three HIVST kits (up to a total maximum of six HIVST kits) from the community facility. A small remuneration of USD1:00 will be paid to the facility owner for each pack of kits distributed. vi. After seven days the helpdesk will contact the second level recipients and steps iv) and v) will be repeated until all kits allocated to a particular community have been distributed. vii. When participants attend a clinic for confirmatory testing, they will return the referral form which was enclosed with the HIVST kit which has a unique barcode and based on their self-reported HIVST result (unreactive/reactive) be screened for PrEP or ART. The outcome of the screening will be recorded in a tick-box on the label and the packaging deposited in a secure box at the clinic from where it will be collected by the study team. viii. Referral forms, HIVST kits and HIVST packaging will be returned to the central data processing facility for data entry and an additional USD1:00 remuneration will be paid to each individual attending the clinic and participating in a confirmatory HIV test. ix. All individuals initiating PrEP or ART will be contacted monthly for six months to provide support and to ascertain whether they are still adhering to/continuing with PrEP/ART.
  3. Additionally, we will contact all men who report they are still taking PrEP/ART at the end of the follow-up period in order to obtain a dry blood spot to verify the self-report of adherence. This will be sent for analysis in order to assess the intracellular levels of tenofovir diphosphate (TFV-DP) in red blood cells.
Conditions
HIV Infections
Being tested
Peer Distribution, Community Health Worker Distribution
Keywords
HIV self test, HIV Pre Exposure Prophylaxis, Peer Networks
Medical subject headings
HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Peer DistributionBehavioural

    In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.

  • Community Health Worker DistributionBehavioural

    Distribution of HIV self tests by community health workers

Study groups in NCT06370923
Study groupRoleWhat they receive
Peer DistributionExperimentalIn intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
Receives: Behavioral: Peer Distribution
Community Health Worker DistributionActive comparatorThis will be the Standard of Care, HIVST kits distributed by Community health workers in the Control clusters.
Receives: Behavioral: Community Health Worker Distribution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HIV pre-exposure prophylaxis (PrEP) initiation

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating PrEP

    Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters

Secondary outcomes (7)
  1. Antiretroviral Therapy initiation

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating Antiretroviral therapy

    Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  2. Antiretroviral Therapy or HIV pre-exposure prophylaxis (PrEP) initiation

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating Antiretroviral therapy

    Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  3. HIV testing

    A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic.

    Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  4. Confirmed positive HIV test

    A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic who are diagnosed HIV positive.

    Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  5. HIV testing after the use of an HIV self test

    A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic after using an HIV test in the previous three months.

    Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters

  6. Attendance at first PrEP follow-up visit

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating PrEP who return for their first follow-up visit.

    Measured: Up to 8 months from the start of HIVST distribution in the local intervention clusters

  7. Attendance at first ART follow-up visit

    A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating ART who return for their first follow-up visit.

    Measured: Up to 8 months from the start of HIVST distribution in the local intervention clusters

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Apr 2024
  2. Study start21 Oct 2024
  3. Primary completion31 May 2028 (estimated)
  4. Study completion31 May 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Cluster randomised trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
3,591 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06370923
Sponsor's protocol ID
1R01MH133488-01
Acronym
IMPERATIVE
Status last verified
May 2025
First submitted
18 Mar 2024
Last updated
4 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Mee P, Otambo W, Skovdal M, Harling G, Pickles M, Dobra A, Hallett T, Barnighausen T, McGowan M, Inghels M, Mandizvidza P, Moorhouse L, Tsenesa B, Maswera R, Dzamatira F, Gregson S, Nyamukapa C, Tanser F. IMPERATIVE: Harnessing male peer networks to enhance engagement with HIV prevention: A large-scale cluster randomised trial to increase HIV self-testing and PrEP uptake among men in Eastern Zimbabwe. Res Sq [Preprint]. 2026 Jun 5:rs.3.rs-9814858. doi: 10.21203/rs.3.rs-9814858/v1.

    PubMed 42281985

Questions about this trial

What is this clinical trial studying?

A study testing Peer Distribution and Community Health Worker Distribution in people with HIV Infections, run by University of Stellenbosch at 1 site in Zimbabwe.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Zimbabwe. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Constance Nyamukapa, PhD (+263 71 480 4050, nyamukapaconnie@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HIV pre-exposure prophylaxis (PrEP) initiation (time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06370923, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in